Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length

Cacciamani, Andrea; Oddone, Francesco; Parravano, Mariacristina; Scarinci, Fabio; Nicola, Marta Di; Lofoco, Giorgio

doi:10.1007/s10384-012-0194-8

Cited by 31 publications

(29 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…found this effect for their group of 22 patients (AL range 20.50–24.60 mm) undergoing injections of 0.1 mL triamcinolone. Cacciamani et al . described such an effect also for their group of 25 patients undergoing Bevacizumab injections of 0.05 mL.…”

Section: Discussionmentioning

confidence: 83%

Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry

Fuest

Kotliar

Walter

et al. 2014

Ophthalmic Physiologic Optic

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 83%

Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry

Fuest

Kotliar

Walter

et al. 2014

Ophthalmic Physiologic Optic

View full text Add to dashboard Cite

show abstract

“…The literature supporting this hypothesis is mixed. 17,38,39,47,71,87 Surprisingly, the volume of injected drug has not been confirmed to be a risk factor. Bakri et al assessed three different volumes (triamcinolone 0.1 mL, pegaptanib 0.09 mL and bevacizumab 0.05 mL) and found no difference in the post-injection IOP change; 10 however, this observation is likely confounded by the variety of needle gauges used for the different medications.…”

Section: Bmentioning

confidence: 99%

The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review

Bracha

Moore

Ciulla

et al. 2018

Survey of Ophthalmology

View full text Add to dashboard Cite

The acute and chronic effects of repeated intravitreal antivascular endothelial growth factor (VEGF) injections on intraocular pressure have not been fully characterized, and the development of sustained ocular hypertension could adversely affect patients who are at risk of glaucomatous optic neuropathy. As expected, volume-driven, acute ocular hypertension immediately follows intravitreal injection, but this pressure elevation is generally transient and well tolerated. Several medications have been investigated to limit acute ocular hypertension following anti-VEGF therapy, but the benefits of pretreatment are not conclusive. Chronic, sustained ocular hypertension, distinct from the short-term acute ocular hypertension after each injection, has also been associated with repeated intravitreal anti-VEGF injections. Risk factors for chronic ocular hypertension include the total number of injections, a greater frequency of injection, and preexisting glaucoma. Proposed mechanisms for chronic ocular hypertension include microparticle obstruction, toxic or inflammatory effects on trabecular meshwork, as well as alterations in outflow facility by anti-VEGF agents. Although limiting anti-VEGF therapy could minimize the risk of both acute and chronic ocular hypertension, foregoing anti-VEGF therapy risks progression of various macular diseases with resulting permanent central vision loss. While definitive evidence of damage to the retinal nerve fiber layer is lacking, patients receiving repeated injections should be monitored for ocular hypertension and patients in whom sustained ocular hypertension subsequently developed should be periodically monitored for glaucomatous changes with optic nerve optical coherence tomography and static visual fields.

show abstract

“…Some investigators assessed the relationship between the post-injection elevation of the IOP and the axial length [27]. They found a positive correlation between shorter axial length and higher post-injection IOP, but only during the 1 to 15 minutes after injection [27, 39, 44]. It was estimated that the rise in IOP after intravitreal bevacizumab (IVB) injection occurs in 0.16% of patients [13].…”

Section: Local Adverse Effectsmentioning

confidence: 99%

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy

Pożarowska

Pożarowski

2016

cejoi

View full text Add to dashboard Cite

Angiogenesis is a clue process for tissue development and function, both in normal and pathological conditions. This process is regulated by multiple molecular systems. One of the most potent is vascular endothelial growth factor (VEGF) and its receptor (VEGFR) system. Members of this family are involved in new vessel formation in embryogenesis and maturation, as well as in reparative or pathological reactions in later stages. They play a substantial role in regeneration, inflammation, wound healing, as well as in cancer pathology. Nowadays it is possible to modulate VEGF-VEGFR interactions in many pathological conditions using anti-VEGF therapy. This therapy has already achieved a grounded position in the management of rheumatological disorders, tumour progression, and metastasis. Such drugs as bevacizumab, ranibizumab, aflibercept, and pegaptanib have also proven to be very effective in the treatment of several ocular diseases, such as age-related macular degeneration (AMD), macular oedema, or proliferative retinopathies and iris neovascularisation. The indications for the application of this therapy in ophthalmology are becoming wider and wider. It may also be used for corneal pathologies and in anti-glaucoma procedures.

show abstract

Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length

Abstract: Patients undergoing intravitreal injection of 0.05 ml of bevacizumab can be exposed to intraocular pressure increases correlated to ocular axial length.

Cited by 31 publications

References 20 publications

Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry

Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry

The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy

Contact Info

Product

Resources

About